For the past year, Amgen has been touting its latest drug, Lumakras, a treatment for non-small cell lung cancer and a particular genetic mutation called KRAS G12C, as its next big blockbuster. A few days ago, the Thousand Oaks-based biotech company got a new sign that its ambitions for Lumakras might prove true. On Sept.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
